A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT03734016 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

652

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Ibrutinib

Sponsor

BeiGene